RESUMEN
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. The recent demonstration of the existence of heteromeric complexes of MT1 and MT2 with 5-HT2C receptors at the cellular level may explain how these two properties of agomelatine translate into a synergistic action that, for example, leads to increases in hippocampal proliferation, maturation and survival through modulation of multiple cellular pathways (increase in trophic factors, synaptic remodelling, glutamate signalling) and key targets (early genes, kinases). The present review focuses on the pharmacological properties of this novel antidepressant. Its mechanism of action, strikingly different from that of conventional classes of antidepressants, opens perspectives towards a better understanding of the physiopathological bases underlying depression.
Asunto(s)
Acetamidas/farmacología , Ansiolíticos/farmacología , Antidepresivos/farmacología , Antagonistas del Receptor de Serotonina 5-HT2/farmacología , Acetamidas/uso terapéutico , Animales , Ansiolíticos/uso terapéutico , Antidepresivos/uso terapéutico , Ansiedad/tratamiento farmacológico , Ritmo Circadiano , Depresión/tratamiento farmacológico , Humanos , Neurogénesis , Receptor de Melatonina MT1/agonistas , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/agonistas , Receptor de Melatonina MT2/metabolismo , Antagonistas del Receptor de Serotonina 5-HT2/uso terapéuticoRESUMEN
Melatonin, or N-acetyl 5-methoxytryptamine, a neurohormone produced in the pineal gland during periods of darkness, plays a key role in the regulation of circadian and seasonal biological rhythms. In mammals, specific MT1 and MT2 receptors are located in the central nervous system, mainly in suprachiasmatic nuclei, and also in a number of peripheral sites. Besides its chronobiotic action on light-dependant functions, such as sleep/waking alternance or seasonal depression, melatonin exerts modulatory effects on immune, endocrine and metabolic functions. However, its short half-life and extensive metabolism lead to a poor bioavailability. This prompted to search for metabolically stable analogs displaying new and innovative properties. The S 20098 compound, a melatoninergic agonist, has proven potent antidepressive and anxiolytic actions. The S 20928 compound, a melatonin antagonist, was shown to enhance basal metabolism and reduce weight gain. Thus, both of these melatonin derivatives open perspectives for the development of innovative therapeutic agents in the fields of depression and obesity.
Asunto(s)
Receptores de Melatonina/agonistas , Receptores de Melatonina/antagonistas & inhibidores , Animales , Humanos , Melatonina/fisiología , Receptores de Melatonina/química , Receptores de Melatonina/genética , Relación Estructura-ActividadRESUMEN
Imidazoline binding sites are present in the striatal complex and in the extended amygdala and have been implicated in mood disorders. In this report we analysed the influence of these sites on the functional activity of the mesolimbic dopaminergic transmission, one of the major brain systems involved in the regulation of motivation and reward. We studied the effects of two imidazoline ligands, S23229 and S23230 (respectively S(+) and R(-) enantiomers of the S22687 or (5-[2-methyl phenoxy methyl] 1,3-oxazolin-2-yl) amine), on extracellular dopamine in the nucleus accumbens using microdialysis in freely moving rats. We compared these imidazoline ligands to cocaine, a dopamine uptake blocker known to increase extracellular dopamine concentrations. S23229 dose-dependently increased extracellular dopamine and locomotor activity. S23230 dose-dependently increased extracellular dopamine and produced a near-significant dose-effect on locomotor activity. S23229 had a stronger efficacy than S23230 and increased dopamine levels in the nucleus accumbens at an extent similar to the one of cocaine. These results suggest that central imidazoline binding sites could contribute to the functional regulation of the mesolimbic dopaminergic system.
Asunto(s)
Dopamina/metabolismo , Núcleo Accumbens/fisiología , Oxazoles/farmacología , Animales , Sitios de Unión , Cocaína/farmacología , Cinética , Ligandos , Masculino , Microdiálisis , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Núcleo Accumbens/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , EstereoisomerismoRESUMEN
A new series of substituted oxygenated heterocycles and thio-analogues were synthesized and evaluated as melatonin receptor ligands. The replacement of the indolic moiety of melatonin by heterocyclic skeleton such as 1,4-benzodioxin, 2,3-dihydro-1,4-benzodioxin, chroman, 2,3-dihydro-1,4-benzoxathiin, thiochroman, carrying the amidic chain on the aromatic ring, leads to compounds showing a weak affinity for melatonin receptors, except for the compounds 1cb and 1hb.
Asunto(s)
Compuestos Heterocíclicos/síntesis química , Melatonina/metabolismo , Oxígeno/química , Animales , Pollos , Estudios de Evaluación como Asunto , Compuestos Heterocíclicos/química , Compuestos Heterocíclicos/metabolismo , Compuestos Heterocíclicos/farmacología , Ligandos , Espectroscopía de Resonancia Magnética , PorcinosRESUMEN
In vivo trans-pineal microdialysis was performed in male Wistar rats maintained under a 12 hr light:12 hr dark (LD 12:12) cycle. Collected dialysates were assayed by radioimmunoassay for melatonin concentrations. A non-linear regression was fitted through the obtained datapoints to determine the time points at which a 50% increase (IT50) and decrease (DT50) of the nocturnal melatonin peak were reached. In a first experiment, the nocturnal melatonin profiles of four animals were determined throughout 5 consecutive days. In a second experiment, we analysed the melatonin profiles during the night in rats originating from three different breeding colonies (Dépré Harlan, and Iffa-Credo). A low intraindividual variability was found on the phase markers IT50 and DT50, as on peak duration of melatonin rhythms estimated over 5 subsequent days in the same animal. In contrast, animals showed a large interindividual variability in their profile phase markers and the values were dependent on the origin of the breeding colony. Each rat colony was characterized by early or late IT50 and DT50 as long or short peak length. It is concluded from experiment 1 that the melatonin rhythm is a very stable circadian marker. Nevertheless, great caution must be taken in the choice of animal groups while studying circadian rhythms due to the large interindividual variability observed in experiment 2. Therefore, as the technique allows the use of the animal as its own control, the present study demonstrated that the use of the microdialysis technique is of interest in studies on the circadian system.
Asunto(s)
Melatonina/metabolismo , Animales , Biomarcadores , Ritmo Circadiano/fisiología , Masculino , Microdiálisis , Glándula Pineal/metabolismo , Ratas , Ratas Wistar , Especificidad de la Especie , Núcleo Supraquiasmático/fisiologíaRESUMEN
1. The MIN6 cell line derived from in vivo immortalized insulin-secreting pancreatic beta cells was used to study the insulin-releasing capacity and the cellular mode of action of S-22068, a newly synthesized imidazoline compound known for its antidiabetic effect in vivo. 2. S-22068, was able to release insulin from MIN6 cells in a dose-dependent manner with a half-maximal stimulation at 100 micronM. Its efficacy (8 fold over the basal value), which did not differ whatever the glucose concentration (stimulatory or not), was intermediate between that of sulphonylurea and that of efaroxan. 3. Similarly to sulphonylureas and classical imidazolines, S-22068 blocked K(ATP) channels and, in turn, opened nifedipine-sensitive voltage-dependent Ca2+ channels, triggering Ca2+ entry. 4. Similarly to other imidazolines, S-22068 induced a closure of cloned K(ATP) channels injected to Xenopus oocytes by interacting with the pore-forming Kir6.2 moiety. 5. S-22068 did not interact with the sulphonylurea binding site nor with the non-I1 and non-I2 imidazoline site evidenced in the beta cells that is recognized by the imidazoline compounds efaroxan, phentolamine and RX821002. 6. We conclude that S-22068 is a novel imidazoline compound which stimulates insulin release via interaction with an original site present on the Kir6.2 moiety of the beta cell K(ATP) channels.
Asunto(s)
Hipoglucemiantes/farmacología , Imidazoles/farmacología , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Piperazinas/farmacología , Canales de Potasio de Rectificación Interna , Antagonistas Adrenérgicos alfa/metabolismo , Animales , Calcio/metabolismo , Canales de Calcio/efectos de los fármacos , Canales de Calcio/metabolismo , Línea Celular , Humanos , Idazoxan/análogos & derivados , Idazoxan/metabolismo , Islotes Pancreáticos/efectos de los fármacos , Potenciales de la Membrana/fisiología , Oocitos/efectos de los fármacos , Oocitos/metabolismo , Bloqueadores de los Canales de Potasio , Canales de Potasio/efectos de los fármacos , Ensayo de Unión Radioligante , Receptor de Insulina/efectos de los fármacos , Radioisótopos de Rubidio , Xenopus laevisRESUMEN
We have investigated the possible mechanisms underlying the antihyperglycaemic effect of the imidazoline derivative S-22068. In vitro, in the presence of 5 mmol/l glucose, S-22068 (100 micromol/l) induced a significant and sustained increase in insulin secretion from isolated, perifused, rat islets and a marked sensitization to a subsequent glucose challenge (10 mmol/l). S-22068 (100 micromol/l was able to antagonize the stimulatory effect of diazoxide on 86Rb efflux from preloaded islets incubated in the presence of 20 mmol/l glucose. Experiments were also performed to investigate whether S-22068 can alter glucose turnover and peripheral insulin sensitivity in vivo in mildly diabetic rats and obese, insulin resistant, Zucker rats. Neither glucose production nor individual tissue glucose utilization was modified by S-22068 in either group of rats. Similar results were obtained whether the studies were performed under basal conditions or during euglycaemic/hyperinsulinemic clamps. The results suggest that S-22068 exerts part of its antihyperglycaemic effect by promoting insulin secretion without alteration of peripheral insulin sensitivity.
Asunto(s)
Glucosa/metabolismo , Hipoglucemiantes/farmacología , Imidazoles/farmacología , Insulina/metabolismo , Piperazinas/farmacología , Animales , Antihipertensivos/farmacología , Diabetes Mellitus Experimental/metabolismo , Diazóxido/farmacología , Glucosa/farmacología , Técnica de Clampeo de la Glucosa , Técnicas In Vitro , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratas , Ratas Wistar , Ratas Zucker , Radioisótopos de Rubidio/farmacocinéticaRESUMEN
Anxiolytic properties of melatonin in rodents had usually been examined in behavioral tests based on stressful situations, i.e., in animal models of "state" anxiety. However, no study reports effects of melatonin on emotionality of rodents submitted to situations devoid of stressful components as in the free-exploratory test, which gives to animals the opportunity to choose freely between familiar and unfamiliar places. This procedure has been proposed as a method for measuring an endogenous form of anxiety called "trait" anxiety. The present study first investigated the effects of melatonin on neophobic responses of male C57BL/6, C3H/He, and BALB/c mice submitted to a free-exploratory test. Results demonstrated that melatonin had no effect in C57BL/6 mice that presented very low neophobic responses, whereas it was effective in reducing neophobia of BALB/c and C3H/He mice that presented, respectively, strong and intermediate avoidance responses towards unfamiliarity. Indeed, mice of both latter strains treated with melatonin made fewer attempts to enter into the unfamiliar compartment, exhibited a lower latency of the first entry into the unfamiliar places, and spent more time in them. Thus, melatonin appeared to be equally effective in reducing "trait" anxiety in both BALB/c and C3H/He mice. Moreover, flumazenil was able to counteract, in a dose-dependent manner, the anxiolytic activity of melatonin in BALB/c, suggesting involvement of central GABAergic system in the pharmacological effects of melatonin.
Asunto(s)
Ansiolíticos/farmacología , Ansiedad/psicología , Conducta Animal/efectos de los fármacos , Melatonina/farmacología , Animales , Conducta Exploratoria/efectos de los fármacos , Flumazenil/farmacología , Moduladores del GABA/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Especificidad de la EspecieRESUMEN
Piperazine derivatives have been identified as new antidiabetic compounds. Structure-activity relationship studies in a series of 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines resulted in the identification of 1-methyl-4-(2', 4'-dichlorobenzyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazine, PMS 812 (S-21663), as a highly potent antidiabetic agent on a rat model of diabetes, mediated by an important increase of insulin secretion independently of alpha2 adrenoceptor blockage. These studies were extended to find additional compounds in these series with improved properties. In such a way, substitution of both piperazine N atoms was first optimized by using various alkyl, branched or not, and benzyl groups. Second, some modifications of the imidazoline ring and its replacement by isosteric heterocycles were carried out, proceeding from PMS 812, to evaluate their influence on the antidiabetic activity. The importance of the distance between the imidazoline ring and the piperazine skeleton was studied third. Finally, the influence of the N-benzyl moiety was also analyzed compared to a direct N-phenyl substitution. The pharmacological evaluation was performed in vivo using glucose tolerance tests on a rat model of type II diabetes. The most active compounds were 1,4-diisopropyl-2-(4', 5'-dihydro-1'H-imidazol-2'-yl)piperazine (41a), PMS 847 (S-22068), and 1,4-diisobutyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazine (41b), PMS 889 (S-22575), which strongly improved glucose tolerance without any side event or hypoglycemic effect. More particularly, PMS 847 proved to be as potent after po (100 micromol/kg) as after ip administration and appears as a good candidate for clinical investigations.
Asunto(s)
Glucemia/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/síntesis química , Imidazoles/síntesis química , Piperazinas/síntesis química , Animales , Bovinos , Corteza Cerebral/metabolismo , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/fisiopatología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Prueba de Tolerancia a la Glucosa , Homeostasis , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Imidazoles/administración & dosificación , Imidazoles/química , Imidazoles/farmacología , Receptores de Imidazolina , Técnicas In Vitro , Inyecciones Intraperitoneales , Insulina/metabolismo , Secreción de Insulina , Corteza Renal/metabolismo , Masculino , Piperazinas/administración & dosificación , Piperazinas/química , Piperazinas/farmacología , Conejos , Ensayo de Unión Radioligante , Ratas , Ratas Wistar , Receptores Adrenérgicos alfa 2/metabolismo , Receptores de Droga/metabolismo , Relación Estructura-ActividadRESUMEN
The aim of the present investigation was to study the effect of neurotoxic ibotenic acid lesion of the retrochiasmatic area on the daily profile of pineal N-acetylserotonin and melatonin synthesis and on the pineal metabolic reactivity to nocturnal short-term retinal photostimulation. Groups of rats were killed 6 h after lights off either in the dark of immediately after being photostimulated for 1 or 15 min. Additionally, groups of rats were sacrificed at six different time points throughout the 24-hour light-dark cycle. The results suggested the presence of two functionally distinct territories in the retrochiasmatic area. The basal retrochiasmatic area, an area situated immediately ventral to the third ventricle, behind the suprachiasmatic nuclei and in front of the arcuate nucleus, is implicated in the nocturnal inhibitory process induced by short-term retinal photostimulation. The lateral retrochiasmatic area, which is situated immediately lateral to the anterior periventricular nucleus, below the anterior hypothalamic nucleus and in front of the ventromedial hypothalamic nucleus, is importantly involved in the control of the peak amplitude of the daily production of N-acetylserotonin and melatonin by the pineal gland.
Asunto(s)
Ácido Iboténico/farmacología , Glándula Pineal/metabolismo , Núcleo Supraquiasmático/fisiología , Animales , Antagonistas de Aminoácidos Excitadores/farmacología , Luz , Masculino , Melatonina/biosíntesis , Ratas , Ratas Wistar , Retina/fisiología , Serotonina/análogos & derivados , Serotonina/biosíntesis , Núcleo Supraquiasmático/efectos de los fármacosRESUMEN
A previous paper reported the synthesis of melatonin receptor ligands. In order to complete the structure-activity relationships and to obtain antagonists to the melatonin receptor, a new series of naphthalenic analogues of melatonin have been synthesized. Modifications include deletion of the 7-methoxy group, replacement of the ethylene moiety, replacement of the amidic function by bioisosteres, and replacement of the naphthalenic nucleus by other bicyclic rings. Almost all the structural modifications lead to decreased affinity for the melatonin receptor. However, the N-n propyl urea derivative (27) is a very potent ligand at this receptor (pKi = 14.3). Most interestingly deletion of the methoxy group resulted in the first antagonist in this series. This molecule, compound 12, or N-[2-(1-naphthyl)-ethyl]cyclobutyl carboxamide has been selected for preclinical development.
Asunto(s)
Amidas/química , Amidas/farmacología , Melatonina/análogos & derivados , Naftalenos/química , Naftalenos/farmacología , Receptores de Superficie Celular/antagonistas & inhibidores , Receptores Citoplasmáticos y Nucleares/antagonistas & inhibidores , Animales , Femenino , Masculino , Naftalenos/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Receptores de Melatonina , Relación Estructura-ActividadRESUMEN
This study addressed the question whether light-suppressed circadian rhythms in cardiovascular parameters in rats could be restored by melatonin and a synthetic analogue. Blood pressure, heart rate, and locomotor activity were monitored by radiotelemetry in six Sprague-Dawley rats. After synchronization to a 12:12 light/dark (LD) schedule (lights on at 0700 hours, 100 lux), rats were kept in constant light (LL) of low intensity (5-10 lux) for 11 weeks. After 3 weeks of LL, rats received daily intraperitoneal (i.p.) injections at 1900 hours of vehicle, the melatonin agonist S-21767 (5 mg/kg) and melatonin (1 mg/kg). Spectral power, 24-h amplitudes and the differences between day and night means were calculated as measures of circadian rhythmicity. During LL a lengthening of the endogenous period to 26 h was observed, which was accompanied by a continuous decrease in circadian amplitude in all parameters monitored until, in the third week of LL, circadian rhythmicity was almost abolished. Neither vehicle, S-21767 nor melatonin were able to restore circadian rhythms in blood pressure and locomotor activity. In contrast, both agonists induced circadian rhythmicity in heart rate in two out of six rats. The day/night difference in heart rate of all animals was significantly increased by S-21767 and, to a smaller extent, by melatonin, whereas the circadian amplitude was not affected. In conclusion, melatonin and the synthetic agonist were able to partially synchronize circadian rhythmicity in heart rate during constant light, but could not restore circadian rhythms in blood pressure.
Asunto(s)
Ritmo Circadiano/efectos de los fármacos , Melatonina/agonistas , Melatonina/farmacología , Animales , Presión Sanguínea/fisiología , Frecuencia Cardíaca/fisiología , Hemodinámica/efectos de los fármacos , Hemodinámica/fisiología , Masculino , Melatonina/biosíntesis , Fotoperiodo , Ratas , Ratas Sprague-DawleyRESUMEN
The effect of intravenous administration of melatonin on the efferent activity of the adrenal nerve was investigated in the rat. Intravenous infusion of 1 or 2 ng melatonin resulted in a decrease, and 10 or 20 ng or larger amount of melatonin caused an increase in the efferent activity of the adrenal nerve. The least effective dose for the suppressive activity of melatonin was 100 pg and the response is dose-related. Administration of either 1 ng or 10 ng of melatonin did not change the plasma glucose concentration until 30 min after the administration. Hepatic vagotomy eliminates the inhibitory effect of melatonin. These results suggest that melatonin sensors in the hepato-portal region and melatonin receptors in the SCN play important roles in the regulation of sympathetic outflow to the adrenal medulla.
Asunto(s)
Glándulas Suprarrenales/inervación , Anticonvulsivantes/farmacología , Melatonina/farmacología , Neuronas Eferentes/efectos de los fármacos , Animales , Glucemia , Desnervación , Inyecciones Intravenosas , Masculino , Potenciales de la Membrana/efectos de los fármacos , Neuronas Eferentes/fisiología , Ratas , Ratas Wistar , Núcleo Supraquiasmático/citología , Núcleo Supraquiasmático/fisiología , VagotomíaRESUMEN
Recent data suggest that some imidazoline derivatives can lower plasma glucose in experimental animal models of diabetes. We studied the activity of an imidazoline S-22068, in rat model of non-insulin-dependent diabetes mellitus (NIDDM) produced with a low dose of streptozotocin (35 mg kg(-1), i.v.) in the adult. The respective increase over basal value in glucose (deltaG) and insulin (deltaI), and the rate of glucose disappearance (K), were measured during a 30 min intravenous glucose tolerance test. After an intraperitoneal injection of S-22068 (24 mg kg(-1)), deltaG (mM min(-1)) was decreased (91.67+/-5.83 vs 120.5+/-3.65; P<0.001), whereas K was increased (1.74+/-0.09 vs 1.18+/-0.05; P<0.001). Although insulinaemia was increased at time-point 0 of the test, deltaI was unchanged. During oral glucose tolerance tests (OGTT), S-22068 (24 mg kg(-1), p.o.) improved glucose tolerance, and its efficiency was potentiated after chronic treatment (15 days). Basal glycaemia was unaffected by the treatment. Under the same conditions, a higher dose of S-22068 (40 mg kg(-1)) further improved glucose tolerance without causing hypoglycaemia. Binding experiments revealed that S-22068 displays no affinity for either adrenoceptors or the two imidazoline receptors I1 or I2. These results demonstrate that S-22068 improves glucose tolerance without causing hypoglycaemia. Thus S-22068 represents a new potential option in the treatment of NIDDM.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Imidazoles/uso terapéutico , Piperazinas , Animales , Glucemia/metabolismo , Relación Dosis-Respuesta a Droga , Prueba de Tolerancia a la Glucosa , Hemodinámica/efectos de los fármacos , Hipoglucemiantes/efectos adversos , Imidazoles/efectos adversos , Insulina/sangre , Insulina/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas WistarRESUMEN
By using quantitative autoradiography, we studied the effects of two drugs related to melatonin on the 2-(125)I-melatonin binding in the pars tuberalis (PT) of rats. The drugs tested were two naphthalenic analogues of melatonin, S-20098 (N-[2-(7-methoxy-1-naphthyl) ethyl] acetamide), an agonist, and S-20928 (N-[2-(1-naphthyl) ethyl] cyclobutyl carboxamide), a putative antagonist. Melatonin (s.c. and i.p.), S-20098 (s.c.), and S-20928 (i.p.) were injected 4 hr before sacrifice. Acute administration of both melatonin and S-20098 decreased melatonin receptor density. In contrast, the putative antagonist S-20928, at a low dose (1 mg/kg), was ineffective on melatonin receptors. It neither affected the 2-(125)I-melatonin specific binding observed in the control group nor did it prevent the decrease in binding induced by melatonin when injected 5 min before the hormone. At a high dose (10 mg/kg), S-20928 totally blocked the effect of melatonin on melatonin receptor density and induced a decrease in binding capacity as melatonin did when injected alone. These results indicate that in the rat pars tuberalis, the melatonin agonist, S-20098, is able to down-regulate melatonin receptors, whereas S-20928 seems to behave as a partial agonist.
Asunto(s)
Acetamidas/farmacología , Melatonina/agonistas , Melatonina/antagonistas & inhibidores , Naftalenos/farmacología , Glándula Pineal/efectos de los fármacos , Receptores de Superficie Celular/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Animales , Autorradiografía , Regulación hacia Abajo/efectos de los fármacos , Masculino , Melatonina/análogos & derivados , Melatonina/metabolismo , Glándula Pineal/metabolismo , Ratas , Ratas Wistar , Receptores de MelatoninaRESUMEN
As the data on circadian variations in plasma glucose or insulin are rather controversial due to interactions with food intake, this work attempted to characterize more precisely the daily rhythm of plasma glucose, insulin, growth hormone and melatonin in rats and to determine whether hormone rhythms occur independently of glucose variations. Plasma glucose, insulin, growth hormone and melatonin were investigated in rats infused for 24 h with a saline (fasted rats) or glucose solution (hyperglycaemic rats). Samples were taken every 2 h during a 24-h period. In fasted rats, both a glucose and an insulin diurnal rhythm were observed. The glucose rhythm was mainly characterized by an increase at the beginning of the night period, similar to that of the dawn phenomenon in humans but in opposite circumstances. Insulin rhythm appeared to be independent of glucose variations as it was still observed in rats maintained in stable hyperglycaemia (13.5 mM). A nycthemeral rhythmicity of growth hormone was observed in fasted and hyperglycaemic rats, with higher fluctuating values during the day period. As expected, plasma melatonin levels were characterized by a rise during the night period in both groups, although the rise was shifted in hyperglycaemic as compared to fasted rats. The main results of this study are the presence of an insulin secretion rhythmicity independent of glucose variations and the existence of a diurnal plasma glucose rhythm, with an increase occurring at the beginning of the night in fasted rats.
Asunto(s)
Glucemia/metabolismo , Ritmo Circadiano/fisiología , Hormona del Crecimiento/sangre , Hiperglucemia/sangre , Insulina/sangre , Melatonina/sangre , Animales , Ayuno/sangre , Masculino , Ratas , Ratas WistarRESUMEN
Since it was known that 5HT properties (5HT1A agonism or 5HT2A antagonism) combined with D2 antagonism may lead to atypical antipsychotic drugs, a series of 19 benzothiazolin-2-one and benzoxazin-3-one derivatives possessing the arylpiperazine moiety was prepared, and their binding profiles were investigated. All tested compounds displayed very high affinities for the 5HT1A and D2 receptors. Therefore, further pharmacological studies were carried out on selected compounds (24, 27, 30, 46, and 47). This evaluation in rats clearly revealed potent antipsychotic properties along with a decrease of extrapyramidal side effects. These derivatives are currently under preclinical development.
Asunto(s)
Antipsicóticos , Oxazinas , Piperazinas , Receptores de Dopamina D2/metabolismo , Receptores de Serotonina/metabolismo , Tiazoles , Animales , Antipsicóticos/síntesis química , Antipsicóticos/química , Antipsicóticos/metabolismo , Antipsicóticos/farmacología , Reacción de Prevención/efectos de los fármacos , Catalepsia/inducido químicamente , Bovinos , Cuerpo Estriado/metabolismo , Dopaminérgicos/síntesis química , Dopaminérgicos/química , Dopaminérgicos/metabolismo , Dopaminérgicos/farmacología , Lóbulo Frontal/metabolismo , Hipocampo/metabolismo , Hipercinesia/tratamiento farmacológico , Ratones , Oxazinas/síntesis química , Oxazinas/química , Oxazinas/metabolismo , Oxazinas/farmacología , Piperazinas/síntesis química , Piperazinas/química , Piperazinas/metabolismo , Piperazinas/farmacología , Conejos , Ratas , Ratas Wistar , Receptores de Serotonina 5-HT1 , Serotoninérgicos/síntesis química , Serotoninérgicos/química , Serotoninérgicos/metabolismo , Serotoninérgicos/farmacología , Sueño/efectos de los fármacos , Conducta Estereotipada/efectos de los fármacos , Relación Estructura-Actividad , Porcinos , Tiazoles/síntesis química , Tiazoles/química , Tiazoles/metabolismo , Tiazoles/farmacologíaRESUMEN
Transgenic hypertensive TGR(mREN2)27 (TGR) rats, carrying an additional mouse renin gene, have been found to show inverse circadian blood pressure profiles compared to normotensive Sprague-Dawley rats. In order to evaluate the contributions of the suprachiasmatic nucleus (SCN) and the neurohormone melatonin to cardiovascular circadian regulation in TGR(mREN2)27 rats and Sprague-Dawley (SPRD) controls, we investigated the effects of melatonin agonist and antagonist treatment in SCN-lesioned and nonlesioned rats, which were kept under conditions of alternating light and darkness (LD). After destruction of the SCN, circadian rhythmicity in blood pressure, heart rate (HR), and motor activity (MA) was almost abolished in rats of both strains. One week of treatment with a synthetic melatonin agonist S-21634 was not able to restore circadian variation in the parameters monitored. In nonlesioned TGR(mREN2)27 rats and Sprague-Dawley control rats, the melatonin antagonist S-22365 had no suppressive effect on LD-synchronized circadian rhythmicity, indicating that LD itself may have a stronger influence on the SCN than endogenous melatonin.
Asunto(s)
Presión Sanguínea/fisiología , Ritmo Circadiano/fisiología , Hipertensión/fisiopatología , Melatonina/fisiología , Renina/metabolismo , Núcleo Supraquiasmático/fisiología , Animales , Animales Modificados Genéticamente , Ritmo Circadiano/efectos de los fármacos , Oscuridad , Frecuencia Cardíaca , Heterocigoto , Hipertensión/genética , Luz , Masculino , Melatonina/agonistas , Ratones , Actividad Motora , Ratas , Ratas Sprague-Dawley , Renina/genética , Núcleo Supraquiasmático/fisiopatologíaRESUMEN
There is some evidence of melatonin implication in the nycthemeral regulation of running activity rhythm in rodents. Because some inbred strains of mice such as C57BL/6 and BALB/c have been generally found to present no nocturnal melatonin peak, in contrast to others such as C3H/He and CBA mice, the aim of this study was to examine the adaptation of daily locomotor activity to a light/dark cycle phase shift in these four strains. An apparatus consisting of two boxes connected by a tunnel was used to record spontaneous locomotor activity, defined as the number of transitions between the two boxes. Locomotor activity was monitored continuously during 3 days before and 14 days after a 12-h phase delay of the light/dark cycle. Results essentially showed that the adaptation of the locomotor activity rhythm to the phase shift was faster in C57BL/6 and BALB/c mice than in C3H/He and CBA mice. This could be related, at least in part, to the differences in melatonin synthesis between the former strains and the latter ones. Although melatonin nocturnal peak is not necessary to a daylight regulation of circadian functions in rodents, it could be considered as an endocrine message that takes part in the anticipation of the following light/dark cycle.